Trials / Completed
CompletedNCT00569114
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients
A Phase 1 Dose-Escalation Pharmacokinetic and Pharmacodynamic Study of TG01 Tablets in Combination With Erlotinib in Non-Small Cell Lung Cancer Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Tragara Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, phase 1, dose escalation study. The purpose is to determine the highest dose of TG01 that can be safely given to patients with Non-Small Cell Lung Cancer in combination with erlotinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG01 | Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-04-01
- Completion
- 2009-11-01
- First posted
- 2007-12-06
- Last updated
- 2010-03-17
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00569114. Inclusion in this directory is not an endorsement.